Type 1 diabetes and pregnancy

Using continuous glucose monitoring for all women with type 1 diabetes during pregnancy could save the UK National Health Service over 9 million pounds per year, report the CONCEPTT investigators.

A prespecified analysis of the CONCEPTT trial shows that pregnant women with type 1 diabetes who were using pumps at baseline did not achieve as good glycemic control as those using multiple daily injections.

Findings from a large cohort study suggest a dose-dependent relationship between the consumption of gluten in pregnancy and the risk for type 1 diabetes in offspring.

The infants of mothers with type 1 diabetes have at least twice the risk for cardiac birth defects as those of mothers without diabetes, with the risk increasing with poorer glycemic control around the time of conception, Swedish study data show.

Research suggests that maternal diabetes increases the offspring’s risk for autism only if it is present during the first two trimesters of pregnancy.

A small study suggests that closed-loop insulin delivery can produce equivalent glycemic control to that of sensor-augmented pump delivery, but with less hypoglycemia, during 1 month of use by pregnant women with type 1 diabetes.

The only diabetes-related Cochrane review published in February aimed to compare the effect of planned versus expectant births on health outcomes among pregnant women with pre-existing diabetes and their infants, but found no relevant trials to review.

Study results suggest that pregnant women with diabetes have a greater risk for adverse birth outcomes than those without diabetes, despite receiving a higher degree of obstetric intervention.

Studies presented in a session on the genetics of diabetes, at the EASD annual meeting in Lisbon, Portugal, demonstrated the heterogeneity of type 1 diabetes risk and the predictive and diagnostic power of a genetic risk score.

The CONCEPTT trial results suggest that the use of continuous glucose monitoring by pregnant women with type 1 diabetes improves glycemic control and neonatal outcomes relative to standard glucose monitoring.

A randomized trial published in The Lancet finds no harm associated with antenatal expressing of breastmilk in low-risk women with diabetes.

The relationship between average blood glucose levels and glycated hemoglobin is altered during pregnancy, show findings based on continuous glucose monitoring.